Skip to main content
EMA Logo
  • Medicines
    Medicines

    • Search
    • Download
    • What we publish and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    Human regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Herbal products
  • Veterinary regulatory
    Veterinary regulatory

    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    Committees

    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    News & events

    • News and press releases
    • Events
    • What's new
    • Committee highlights
    • Therapeutic areas: latest updates
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    Partners & networks

    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Academia
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    About us

    • What we do
    • Who we are
    • How we work
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • FAQs
    • Contacts

COVID-19

All info here

QUICK LINKS

  • Latest updates
  • Vaccines
  • Treatments
  • Guidance for developers and companies
  • Reports of falsified Ozempic pens
    Falsified medicines |Ozempic

    Reports of falsified Ozempic pens

  • Reports of falsified Ozempic pens
    Falsified medicines |Ozempic

    Reports of falsified Ozempic pens

    EMA alerts EU patients and healthcare professionals that pre-filled pens falsely labelled as the diabetes medicine Ozempic have been identified at wholesalers in EU and the UK

  • CHMP Highlights: October 2023
    CHMP slider image
    MEDICINES |COMMITTEES

    CHMP Highlights: October 2023

  • CHMP Highlights: October 2023
    CHMP slider image
    MEDICINES |COMMITTEES

    CHMP Highlights: October 2023

    EMA's human medicines committee (CHMP) recommended 7 new medicines for approval in the EU at its October 2023 meeting

  • Management Board: Highlights of October 2023 meeting
    Management Board meeting highlights
    Management Board |Highlights

    Management Board: Highlights of October 2023 meeting

  • Management Board: Highlights of October 2023 meeting
    Management Board meeting highlights
    Management Board |Highlights

    Management Board: Highlights of October 2023 meeting

    The Board adopted revised transparency rules for the Clinical Trials Information System and was updated on EMA’s activities in the first half of 2023

  • Revision of transparency rules for clinical trials
    Slider for revision of transparency rules for clinical trials
    Clinical Trials |Regulatory

    Revision of transparency rules for clinical trials

  • Revision of transparency rules for clinical trials
    Slider for revision of transparency rules for clinical trials
    Clinical Trials |Regulatory

    Revision of transparency rules for clinical trials

    EMA revised rules to give faster access to information in the EU Clinical Trials Information System

Search for medicines
Search for information on human, veterinary or herbal medicines.
What's new
Find all the latest news and updates published on this website in one place.
FAQs
Find answers to the most frequently asked questions we receive.

Latest news

  • List item
    18/10/2023

    EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens

    The European Medicines Agency has been notified by relevant national competent authorities that pre-filled pens falsely labelled as the diabetes medicine Ozempic (semaglutide, 1 mg, solution for injection) have been identified at wholesalers in the...

  • List item
    13/10/2023

    New treatment option for heavily pre-treated multiple myeloma patients

    EMA’s human medicines committee (CHMP) has recommended a conditional marketing authorisation in the European Union (EU) for Elrexfio (elranatamab) as a monotherapy (used on its own) for the treatment of adult patients with relapsed and refractory...

  • List item
    13/10/2023

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023

    Seven new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2023 meeting. The CHMP adopted a positive opinion for Agamree * (vamorolone), for the treatment of Duchenne...

  • List item
    06/10/2023

    Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 October 2023

    The Committee adopted by consensus a positive opinion for a marketing authorisation Nobivac LoVo L4 (a duplicate of Nobivac L4), from Intervet International B.V., a vaccine for the active immunisation of of dogs against Leptospira interrogans...

  • List item
    06/10/2023

    EMA Management Board: highlights of October 2023 meeting

    EMA’s Management Board met on 5 October in Amsterdam. Clinical trials in the EU The Board adopted revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System (CTIS). The...

  • List item
    06/10/2023

    Revised transparency rules for the EU Clinical Trials Information System (CTIS)

    EMA has adopted revised transparency rules for the publication of information on clinical trials submitted through the Clinical Trials Information System . The simplifications introduced will give access to clinical trial information to stakeholders...

  • Load more news

Information for you

Patients and carers
Featured news and updates for patients and carers
Healthcare professionals
Featured news and updates for healthcare professionals, including doctors, nurses and pharmacists
Animal health professionals
Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners
Pharmaceutical industry
Featured news and updates for pharmaceutical industry stakeholders active in the human and veterinary medicines fields
Media
Featured news and updates for journalists with a professional interest in the development and availability of medicines in the European Union
Academia
Featured news and updates for European academics and researchers in the field of medicine development

Key content

  • List item

    Product emergency hotline

  • List item

    UK’s withdrawal from the EU

  • List item

    PRIME: Priority medicines

  • List item

    Pharmacovigilance (safety monitoring)

  • List item

    Data on medicines

  • List item

    Clinical data publication

  • List item

    Careers

Services & databases

  • List item

    Clinical Trials website

  • List item

    Account Management portal

  • List item

    eSubmission

  • List item

    EudraVigilance (human)

  • List item

    EudraVigilance Veterinary

  • List item

    Veterinary Medicines information website

  • List item

    Suspected adverse drug reactions database

  • List item

    Clinical data

  • List item

    SPOR data management services

  • List item

    Service Desk

  • List item

    IRIS platform

  • List item

    Public register of parallel distribution notices

  • List item

    European Vaccination Information Portal

How does EMA work?

  • List item

    What we do

  • List item

    Our role in authorisation of medicines

  • List item

    Who we are

  • List item

    Our scientific experts

  • List item

    How we work

  • List item

    What we publish

Product emergency hotline
outside working hours
  • About us
  • What we do
  • Careers
  • Committees
  • Regulatory network
  • Languages
  • Frequently asked questions
  • Glossaries
  • About this website
  • Privacy
  • Search tips
  • Access to documents
  • Contacts
  • Send a question
  • EMA Service desk (system support)

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us

Postal address and deliveries

Business hours and holidays

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
RSS feed Twitter YouTube LinkedIn
© 1995-2023 European Medicines Agency
European Union agencies network
European Union agencies network
An agency of the European Union
European Union flag